Specific Properties of Vitamin D and Immunocorrectors in the Prevention of Fracture Complications

In recent years, more and more attention has been paid to modifiable factors affecting recovery from severe fractures. One of these factors is vitamin D, a hormone that regulates mineral metabolism and immunity. Vitamin D deficiency is extremely common: about 50-70% of trauma patients have a level of 25(OH)D is below the norm [1]. Studies have linked vitamin D deficiency to an increased risk of infectious complications (pneumonia, urinary tract infections) and even thromboembolism in patients with severe injuries [2]. In addition, vitamin D deficiency can slow down osteogenesis, leading to a longer period of bone fusion [3, 2]. Against the background of deficiency, there is often a concomitant imbalance of immunoglobulins and cytokines. Correction of vitamin D deficiency and targeted immunocorrection (for example, the introduction of immunoglobulins) in the acute period of injury will reduce the incidence of purulent complications and improve outcomes.